MedImmune has secured orphan drug designation from the the US Food and Drug Administration (FDA) for its MEDI-551 neuromyelitis optica drug.
MEDI-551 is an anti-CD19 monoclonal antibody indicated to treat neuromyelitis optica and neuromyelitis optica spectrum disorders.